Hebei Weimiao Biology Co., LTD 1
Location
  • Home
  • Terazosin Hydrochloride | CAS 63074-08-8 - Comprehensive Guide

Zář . 06, 2024 20:48 Back to list

Terazosin Hydrochloride | CAS 63074-08-8 - Comprehensive Guide



Terazosin Hydrochloride A Comprehensive Overview


Terazosin hydrochloride, a pharmacological agent belonging to the class of alpha-adrenergic blockers, is primarily used in the management of hypertension and benign prostatic hyperplasia (BPH). Its chemical structure, identified by the CAS number 63074-08-8, underscores its significance in clinical applications, particularly in improving the quality of life for patients suffering from conditions related to increased urinary frequency and elevated blood pressure.


Mechanism of Action


Terazosin works by selectively antagonizing alpha-1 adrenergic receptors in vascular smooth muscle, leading to vasodilation and a subsequent decrease in vascular resistance. This action is integral in reducing blood pressure in hypertensive patients. Additionally, by blocking these receptors in the prostate and bladder neck, terazosin alleviates urinary obstruction, fostering improved urinary flow rates and decreasing symptoms associated with BPH, such as nocturia, urgency, and incomplete bladder emptying.


Clinical Uses

Terazosin is primarily indicated for the treatment of hypertension and BPH. In hypertensive patients, it can be used alone or in combination with other antihypertensive agents for a synergistic effect. In terms of BPH, it has become a go-to medication for many physicians due to its effectiveness in relieving urinary symptoms without the side effects commonly associated with surgical interventions.


china cas 63074-08-8 terazosin hydrochloride

china cas 63074-08-8 terazosin hydrochloride

Dosage and Administration


The dosing of terazosin is usually initiated at a low dose to mitigate potential side effects, such as first-dose syncope, a phenomenon where patients experience a sudden drop in blood pressure upon standing. Physicians often start patients on a 1 mg dose at bedtime, which may be titrated to a maximum of 10 mg based on the individual patient’s response and tolerability. It is crucial for patients to adhere to their prescribed regimen and maintain regular follow-up appointments to optimize their treatment.


Side Effects and Precautions


While terazosin is generally well tolerated, some patients may experience side effects, including dizziness, fatigue, headache, and nasal congestion. The risk of orthostatic hypotension—especially after the first dose—necessitates patient education on the importance of rising slowly to prevent falls. Additionally, caution should be exercised in patients with a history of hypotension, hepatic impairment, or those taking other medications that may interact with alpha-blockers.


Conclusion


In summary, terazosin hydrochloride represents a vital component in managing both hypertension and BPH. Its dual action not only enhances patient well-being through improved urinary flow and reduced blood pressure but also exemplifies the importance of pharmacological interventions in chronic disease management. Continued research and clinical practice will further elucidate the benefits and potential applications of this medication, ensuring that patients receive comprehensive and effective care in addressing their health needs. As with all medications, open communication between patients and healthcare providers is essential in maximizing therapeutic outcomes while minimizing risks.


Share
Next：

Latest news

If you are interested in our products, you can choose to leave your information here, and we will be in touch with you shortly.


Hit enter to search or ESC to close
cs_CZCzech
en_USEnglish afAfrikaans sqAlbanian amAmharic arArabic hyArmenian azAzerbaijani euBasque belBelarusian bn_BDBengali bs_BABosnian bg_BGBulgarian caCatalan cebCebuano zh_CNChina zh_TWChina (Taiwan) coCorsican hrCroatian da_DKDanish nl_NLDutch eoEsperanto etEstonian fiFinnish fr_FRFrench fyFrisian gl_ESGalician ka_GEGeorgian de_DEGerman elGreek guGujarati htHaitian Creole haHausa hawHawaiian he_ILHebrew hi_INHindi hmnMiao hu_HUHungarian is_ISIcelandic igIgbo id_IDIndonesian gaIrish it_ITItalian jaJapanese jvJavanese knKannada kkKazakh kmKhmer rwRwandese ko_KRKorean ckbKurdish kyKyrgyz loLao laLatin lvLatvian lt_LTLithuanian lbLuxembourgish mk_MKMacedonian mgMalgashi ms_MYMalay ml_INMalayalam mtMaltese miMaori mrMarathi mnMongolian my_MMMyanmar ne_NPNepali nb_NONorwegian nyNorwegian orOccitan psPashto fa_IRPersian pl_PLPolish pt_PTPortuguese pa_INPunjabi ro_RORomanian ru_RURussian smSamoan gdScottish Gaelic sr_RSSerbian stSesotho snShona sdSindhi si_LKSinhala sk_SKSlovak sl_SISlovenian soSomali es_ESSpanish suSundanese swSwahili sv_SESwedish tlTagalog tgTajik ta_INTamil tt_RUTatar teTelugu thThai tr_TRTurkish tkTurkmen ukUkrainian urUrdu ug_CNUighur uz_UZUzbek viVietnamese cyWelsh xhBantu yiYiddish yoYoruba zuZulu cs_CZCzech